New drugs for the treatment of Mycobacterium tuberculosis infection

Publication date: July 2017
Source:Biomedicine & Pharmacotherapy, Volume 91
Author(s): Manaf AlMatar, Husam AlMandeal, Işıl Var, Begüm Kayar, Fatih Köksal
Tuberculosis presents a grave challenge to health, globally instigating 1.5 million mortalities each year. Following the breakthrough of first-line anti-TB medication, the number of mortalities reduced greatly; nonetheless, the swift appearance of tuberculosis which was drug-resistant, as well as the capability of the bacterium to survive and stay dormant are a considerable problem for public health. In order to address this issue, several novel possible candidates for tuberculosis therapy have been subjected to clinical trials of late. The novel antimycobacterial agents are acquired from different categories of medications, operate through a range of action systems, and are at various phases of advancement. We therefore talk about the present methods of treating tuberculosis and novel anti-TB agents with their action method, in order to advance awareness of these new compounds and medications.

Graphical abstract

http://ift.tt/2pmk01d